NUVA Stock Recent News
NUVA LATEST HEADLINES
Globus Medical faced market backlash post-merger with NuVasive, but Q1 FY 2024 showed strong growth and integration efforts. Management revised net sales guidance for FY 2024, aiming for high growth and increased profits with lower operating costs. Valuation scenarios suggest potential for risk capital unlock, and a buy rating is supported on fundamentals and cash flow estimates.
NuVasive's (NUVA) strong sales across the U.S. Spinal Hardware and U.S. Surgical Support businesses instill optimism.
NuVasive, Inc. (NASDAQ:NUVA ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Chris Barry - Chief Executive Officer Matt Harbaugh - Executive Vice President and Chief Financial Officer Conference Call Participants Matthew Miksic - Barclays Bank Vikramjeet Chopra - Wells Fargo Securities Allen Gong - JP Morgan Joshua Jennings - Cowan Shagun Chadha - RBC David Saxon - Needham Matt Taylor - Jefferies Matthew Blackman - Stifel Operator Good day, ladies and gentlemen, and welcome to the NuVasive First Quarter 2023 Earnings Conference Call. I would now like to introduce your host for today's call, Ms.
NuVasive (NUVA) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.54 per share a year ago.
Globus Medical caught headlines after announcing the NuVasive merger. Investors have wiped out considerable equity post-announcement, but the worst may be now priced in.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock?
NuVasive (NUVA) receives FDA 510(k) clearance for using the Precice limb lengthening system for treating pediatric patients.
According to NuVasive (NUVA), the combined company is set to have an advanced commercial scale and portfolio of clinically proven solutions.
Softer results for spinal surgery innovator plus questionable merger have dropped estimates and shares